850 PATIENTS WITH MAFLD TAKING GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT HAVE HIGHER INCIDENCE FOR HEPATOBILIARY CANCER BUT HAVE LOWER OVERALL ...
reviewer4you.com
Su1558 GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS REDUCE HEPATIC FAT CONTEXT INDEPENDENT OF THE WEIGHT LOSS IN DIABETIC PATIENTS WITH METABOLIC ...
Sa1451 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS USE DOES NOT INCREASE THE RISK FOR ACUTE PANCREATITIS AND IS ASSOCIATED WITH LOWER COMPLICATIONS IN ...
Sa1959 NO INCREASED RISK OF DE-NOVO ACUTE PANCREATITIS IN NONDIABETIC WITH OBESITY PATIENTS ON GLP-1 RECEPTOR AGONISTS FOR WEIGHT LOSS: A MULTI-NETWORK ...
Hepatocellular carcinoma (HCC) is a leading cause of cancer death. HCC is preventable with about 70 percent of HCC attributable to modifiable risk factors. ...
JG Hashash et al. Clin Gastroenterol Hepatol 2024; 22: 705-707. Open Access! AGA Rapid Clinical Practice Update on the Management of Patients Taking ...
GLP1 receptor agonists and post-endoscopic aspiration pneumonia: what plays a role in clinical practice?
Do GLP1 receptor agonists cause post-endoscopic aspiration pneumonia?
Measuring the quality and safety of upper endoscopy in patients taking glucagon-like peptide-1 receptor agonists